Clinical Trial Update: Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of two raltegravir dosing regimens in ART-naive HIV-1 infected patients receiving rifampin for active tuberculo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• RIFAMPIN (RIFAMPIN)
• Raltegravir (Isentress) (raltegravir)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: HIV Infections, Tuberculosis | Phase 2 | Status: COMPLETED